Aclarubicin

Bezeichnung:Aclarubicin

CAS-Nr57576-44-0

Englisch Name:Aclarubicin

CBNumberCB4188966

SummenformelC42H53NO15

Molgewicht811.88

MOL-Datei57576-44-0.mol

Synonyma

Aclarubicin

Aclarubicin physikalisch-chemischer Eigenschaften

Schmelzpunkt	151-153° (dec)
alpha	D24 -11.5° (c = 1 in methylene chloride)
Siedepunkt	756.05°C (rough estimate)
Dichte	1.2261 (rough estimate)
Brechungsindex	1.6220 (estimate)
storage temp.	2-8°C
Löslichkeit	Dichloromethane (Slightly), DMSO (Slightly), Methanol (Slightly)
Aggregatzustand	Yellow powder with orange cast.
pka	6.41±0.70(Predicted)
Farbe	Yellow powder
Stabilität	Light Sensitive
CAS Datenbank	57576-44-0(CAS DataBase Reference)

Sicherheit

Kennzeichnung gefährlicher	T
R-Sätze:	25
S-Sätze:	36/37/39-45
RIDADR	3249
RTECS-Nr.	QI9279300
HazardClass	6.1(a)
PackingGroup	II
Toxizität	LD50 in mice (mg/kg): 22.6 i.p., 33.7 i.v. (Oki)

Gefahreninformationscode (GHS)

Aclarubicin Chemische Eigenschaften,Einsatz,Produktion Methoden

R-Sätze Betriebsanweisung:
R25:Giftig beim Verschlucken.
S-Sätze Betriebsanweisung:
S36/37/39:Bei der Arbeit geeignete Schutzkleidung,Schutzhandschuhe und Schutzbrille/Gesichtsschutz tragen.
S45:Bei Unfall oder Unwohlsein sofort Arzt zuziehen (wenn möglich, dieses Etikett vorzeigen).
Beschreibung
Aclarubicin was found in the culture broth of Streptomyces galilaeus MA144-M1 by Umezawa et al. of the Institute of Microbial Chemistry in 1975. It was produced along with structurally related compounds showing antileukemic activity and named aclacinomycin A. Sanraku-Ocean cooperated in isolating aclacinomycin A as a yellow crystalline powder and evaluated its strong antileukemic activity and low cardiac toxicity. Its generic name was changed to aclarubicin on the recommendation of the World Health Organization.
Originator
Aclacinon ,Yamanouchi ,Japan ,1981
Verwenden
Antineoplastic.
Verwenden
Aclarubicin is an anthracycline antibiotic. It is used in the treatment of cancer.
Definition
ChEBI: An anthracycline antibiotic that is produced by Streptomyces galilaeus and also has potent antineoplastic activity.
Manufacturing Process
100 ml of this medium was sterilized at 120°C for 15 min in a 500 ml Sakaguchi-shaking flask which was inoculated from an agar slant culture of Streptomyces galilaeus MA144-M1 by platinum loop. Incubation proceeded for 48 hr at 28°C on a reciprocal shaker. 10 L of the previously sterilized medium in a 20 L stainless steel jar fermenter were aseptically inoculated with 200 ml of the above seed cultures. Fermentation was carried out at 28°C for 32 hours with agitation (240 rpm) and aeration (5 L/min). The cultured broth obtained was adjusted to pH 4.5, mixed with an adsorbent siliceous earth material and filtered from the mycelium. The filtrate and cake obtained thereby were extracted separately. The cake was suspended in acetone (3 L/kg wet cake), stirred for 2 hr and filtered, and the cake was further extracted with acetone once again. The extracts thus obtained were evaporated to one-tenth volume in vacuum. The culture filtrate was adjusted to pH 6.8 and extracted twice with one-third volume of ethyl acetate, and the ethyl acetate extracts were concentrated to one-tenth volume in vacuum.
Twenty grams of the resulting oily substances were mixed with 20 grams of silicic acid (Mallinckrodt Chemical Co.), applied to a column 40 cm in length and 4.5 cm in diameter filled with silicic acid, and eluted with a benzeneacetone- methanol mixture. The initial eluate which eluted with a 1:1:0 mixture was discarded and the active fractions eluted with 1:3:0 and 1:3:0.3 mixtures were collected and concentrated to dryness in vacuum. 11.5 g of this crude substance was then dissolved in a small amount of ethyl acetate and applied to the same silicic acid column as above. After discarding the initial eluates by the 1:1 and 2:1 benzene-acetone mixtures, aclacinomycin B fractions were first eluted with the above mixtures of 1:3 and 1:5 ratio, and aclacinomycin A fractions were then eluted with the 1:5:0.5 and 1:5:1 benzene-acetone-methanol mixtures. The eluates were dried over anhydrous sodium sulfate and concentrated to dryness in vacuum. 4.8 g of crude aclacinomycin A and 3.5 g of aclacinomycin B were obtained as yellow powder. 2.0 g of crude aclacinomycin A obtained as above were dissolved in a small amount of chloroform, applied to a column 20 cm in length and 20 cm in diameter filled with 30 g of silicic acid. After eluting off the pigments containing aglycone and aclacinomycin B and other impurities with chloroform and 1.5% methanol-containing chloroform, aclacinomycin A fractions were eluted with 2% methanol-containing chloroform, and concentrated to dryness in vacuum. 53 mg of yellow powder of aclacinomycin A was obtained. Its melting point was 129°C to 135°C.
Therapeutic Function
Antitumor, Antibiotic
Biologische Aktivität
aclacinomycin a is a dual inhibitor of topoisomerase i and ii [1]. aclacinomycin a is an anticancer drug which can reduce the tumor with minimal damage to normal cells. aclacinomycin a shows potency against a wide variety of solid tumours and haematological malignancies. in a549, hepg2 and mcf-7 cells, aclacinomycin a shows cytotoxic activity with ic50 values of 0.27μm, 0.32μm and 0.62μm, respectively. aclacinomycin a induces cell apoptosis in these cells and the effects change to be necrosis when the incubation time is prolonged. aclacinomycin a is demonstrated to increase the activity of both caspase-3 and caspase-8, thus inducing the activation of parp. apart from that, as an inhibitor of opoisomerases, aclacinomycin a is found to induce dna damage in v79 and irs-2 cells. aclacinomycin a is used to treat acute leukaemias, lymphomas and other solid tumors through its inhibition of topo ii [1, 2].
Sicherheitsprofil
Poison by ingestion,intraperitoneal, subcutaneous, and intravenous routes. Anexperimental teratogen. Other experimental reproductiveeffects. Mutation data reported. An eye and subcutaneousirritant. When heated to decomposition it emits toxicfumes of
Enzyminhibitor
This non-peptidic aclacinomycin antibiotic (FW = 811.88 g/mol; CAS CAS 57576-44-0; Source: strain of Streptomyces galilaeus), also known as aclarubicin, induces DNA strand scission. Target(s): nitric oxide synthase; RNA biosynthesis; DNA polymerase I; RNA polymerase, Escherichia coli; reverse transcriptase, avian myeloblastosis virus; Na+/K+-exchanging ATPase; Ca2+-transporting ATPase; cyclicnucleotide phosphodiesterase; electron transport and oxidative phosphorylation, mitochondrial; DNA helicase; DNA topoisomerase II; 20S proteasome, chymotrypsin-like activity; DNA topoisomerase I; 3'-5' DNA helicase, Plasmodium falciparum.
target
20S proteasome
Einzelnachweise
[1] hajji n, mateos s, pastor n, domínguez i, cortés f. induction of genotoxic and cytotoxic damage by aclarubicin, a dual topoisomerase inhibitor. mutat res. 2005 may 2;583(1):26-35.
[2] rogalska a, szwed m, jó wiak z. aclarubicin-induced apoptosis and necrosis in cells derived from human solid tumours. mutat res. 2010 jul 19;700(1-2):1-10.

Aclarubicin Upstream-Materialien And Downstream Produkte

Aclarubicin Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

57576-44-0, Aclarubicin Verwandte Suche:

Send Inquriy